Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers
Authors
Keywords
-
Journal
DRUGS
Volume 78, Issue 7, Pages 747-758
Publisher
Springer Nature
Online
2018-04-16
DOI
10.1007/s40265-018-0903-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study
- (2018) Baorang Zhu et al. CANCER BIOLOGY & THERAPY
- Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
- (2018) Alice Lee et al. CANCER TREATMENT REVIEWS
- Challenges and Opportunities With Oncology Drug Development in China
- (2018) Gaurav Bajaj et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus
- (2018) David H. Ilson et al. GASTROENTEROLOGY
- A phase II study of apatinib in patients with recurrent epithelial ovarian cancer
- (2018) Mingming Miao et al. GYNECOLOGIC ONCOLOGY
- Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma
- (2018) Wen-Chang Yu et al. MEDICINE
- Cancer molecular markers: A guide to cancer detection and management
- (2018) Meera Nair et al. SEMINARS IN CANCER BIOLOGY
- Targeted Therapies for Pancreatic Cancer
- (2018) Idoroenyi Amanam et al. Cancers
- Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance
- (2017) Fang Li et al. EUROPEAN JOURNAL OF CANCER
- Angiogenesis inhibitors in early development for gastric cancer
- (2017) Mauricio P. Pinto et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole
- (2017) Xiaoyun Liu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- P2.01-011 The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma
- (2017) Q. Shi et al. Journal of Thoracic Oncology
- P1.07-053 Apatinib for Chemotherapy-Refractory Extensive Stage SCLC: Results from a Single-Center Retrospective Study
- (2017) Wei Hong et al. Journal of Thoracic Oncology
- Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
- (2017) Jianqiang Li et al. OncoTargets and Therapy
- Salvage treatment with apatinib for advanced non-small-cell lung cancer
- (2017) Zhengbo Song et al. OncoTargets and Therapy
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors
- (2016) Mingming Yu et al. CLINICAL PHARMACOKINETICS
- Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer
- (2016) Hong-Dou Chen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
- (2016) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology
- (2016) Jaffer A. Ajani et al. Journal of the National Comprehensive Cancer Network
- Apatinib — new third-line option for refractory gastric or GEJ cancer
- (2016) Toru Aoyama et al. Nature Reviews Clinical Oncology
- Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma
- (2016) Hong Peng et al. Oncotarget
- Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
- (2015) Liya Liu et al. OncoTargets and Therapy
- Apatinib for the treatment of gastric cancer
- (2014) Ruixuan Geng et al. EXPERT OPINION ON PHARMACOTHERAPY
- Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer
- (2014) Xichun Hu et al. INTERNATIONAL JOURNAL OF CANCER
- Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy
- (2013) Minhao Fan et al. BREAST CANCER RESEARCH AND TREATMENT
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells
- (2011) Xiu-zhen Tong et al. BIOCHEMICAL PHARMACOLOGY
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters
- (2010) Y.-j. Mi et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started